AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17822829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dominant hand position during UCC-CPR
Number of subjects: 59
Study 17822829 — intervention group
Group type: COMPARATOR
Intervention: Non-dominant hand position during UCC-CPR
Number of subjects: 59
Study 16162034 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccination (gp100 antigen)
Number of subjects: 10
Study 12834650 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamblers Anonymous (GA) attendance
Number of subjects: 342
Study 12834650 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of professional sessions attended during treatment
Number of subjects: 342
Study 12834650 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of GA meetings attended during treatment
Number of subjects: 342
Study 12834650 — intervention group
Group type: COMPARATOR
Intervention: Non-GA attendees
Number of subjects: 342
Study 10565804 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly 12.5 mg intramuscular injections of fluphenazine decanoate
Number of subjects: 58
Study 10565804 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly 1.5 mg intramuscular injections of fluphenazine decanoate
Number of subjects: 58
Study 8560997 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of expectant management
Number of subjects: 205
Study 8560997 — intervention group
Group type: COMPARATOR
Intervention: 24 hours of expectant management
Number of subjects: 205
Study 1844268 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 30 mg/day plus retinyl palmitate 25,000 IU/day
Number of subjects: 8129
Study 1844268 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 8129
Study 6760030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (3% ophthalmic ointment, 5 times a day for 14 days)
Number of subjects: 64
Study 6760030 — intervention group
Group type: COMPARATOR
Intervention: Idoxuridine (0.5% ophthalmic ointment, 5 times a day for 14 days)
Number of subjects: 64
Study 6760030 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 64
Study 6760030 — intervention group
Group type: COMPARATOR
Intervention: Idoxuridine
Number of subjects: 64
Study 31971677 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination at baseline
Number of subjects: 24269
Study 31971677 — intervention group
Group type: COMPARATOR
Intervention: Control group (4CMenB vaccination at 12 months)
Number of subjects: 24269
Study 31971677 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination
Number of subjects: 24269
Study 31971677 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for carriage (baseline assessment)
Number of subjects: 24269
Study 31252655 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 3 mg/kg/b.m. (CAF‐3)
Number of subjects: 15
Study 31252655 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 6 mg/kg/b.m. (CAF‐6)
Number of subjects: 15
Study 31252655 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg/kg/b.m. (CAF‐9)
Number of subjects: 15
Study 31252655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 15
Study 29757459 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual meaning-centered psychotherapy (IMCP)
Number of subjects: 321
Study 29757459 — intervention group
Group type: COMPARATOR
Intervention: Supportive psychotherapy (SP)
Number of subjects: 321
Study 29757459 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 321
Study 25908532 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g)
Number of subjects: 85
Study 25908532 — intervention group
Group type: COMPARATOR
Intervention: Control (4 g olive oil)
Number of subjects: 85
Study 24698990 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) with 21% naturally occurring GMP
Number of subjects: 22
Study 24698990 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) with 2% naturally present GMP
Number of subjects: 22
Study 24698990 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) isolate
Number of subjects: 22
Study 24698990 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin carbohydrate
Number of subjects: 22
Study 21084552 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 39
Study 21084552 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 39
Study 21084552 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone and Olanzapine
Number of subjects: 39
Study 20668151 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized simulated learning intervention
Number of subjects: 41
Study 20668151 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention clinics)
Number of subjects: 41
Study 16899309 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 4
Study 16899309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 16113020 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign-born women
Number of subjects: 382
Study 16113020 — intervention group
Group type: COMPARATOR
Intervention: Continental US born women
Number of subjects: 382
Study 12166584 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (500 microg b.i.d.)
Number of subjects: 15
Study 12166584 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (50 microg b.i.d.)
Number of subjects: 15
Study 12166584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 15
Study 10378852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine infusion (0.7 to 1.4 microg/kg/min)
Number of subjects: 77
Study 10378852 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (0.5 to 1 microg/kg/min)
Number of subjects: 77
Study 10378852 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 77
Study 8710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine treatment with a low calorie diet
Number of subjects: 19
Study 8710426 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet only)
Number of subjects: 19
Study 8710426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine treatment
Number of subjects: 19
Study 1804863 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 10
Study 6667628 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bendrofluazide
Number of subjects: 24
Study 6667628 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg bumetanide
Number of subjects: 24
Study 6667628 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamide
Number of subjects: 24
Study 31587658 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal GTN (5 mg)
Number of subjects: 145
Study 31587658 — intervention group
Group type: COMPARATOR
Intervention: Sham dressing
Number of subjects: 145
Study 29525821 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (2 loading doses of 80 mg before and 24 hours after PCI)
Number of subjects: 4191
Study 29525821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo before and 24 hours after PCI)
Number of subjects: 4191
Study 30640985 — intervention group
Group type: EXPERIMENTAL
Intervention: Xingfeng Capsule (XFC), 3 pills each time, three times per day for 3 months
Number of subjects: 76
Study 30640985 — intervention group
Group type: COMPARATOR
Intervention: Leflunomide (LEF), 10 mg each time, once per day for 3 months
Number of subjects: 76
Study 23836484 — intervention group
Group type: EXPERIMENTAL
Intervention: Fused Deposition Modelling (FDM) orthosis
Number of subjects: 15
Study 23836484 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Laser Sintering (SLS) orthosis
Number of subjects: 15
Study 23836484 — intervention group
Group type: COMPARATOR
Intervention: Standard Foot Orthosis (SFO)
Number of subjects: 15
Study 22258265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (100,000 IU cholecalciferol given every 2 months) and calcium (1 g/d)
Number of subjects: 59
Study 22258265 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 59
Study 22258265 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium supplementation
Number of subjects: 59
Study 20073463 — intervention group
Group type: EXPERIMENTAL
Intervention: Berry group (160 g/day of bilberries, lingonberries, black currants, and chokeberries)
Number of subjects: 72
Study 17623077 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 325
Study 17623077 — intervention group
Group type: COMPARATOR
Intervention: Expectant management with maternal and fetal monitoring
Number of subjects: 325
Study 16226521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of 4 mg triamcinolone acetonide (TA)
Number of subjects: 56
Study 16226521 — intervention group
Group type: COMPARATOR
Intervention: Macular laser grid photocoagulation (MLG)
Number of subjects: 56
Study 16226521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 4 mg TA followed by MLG
Number of subjects: 56
Study 12107236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, orally, three times daily)
Number of subjects: 7
Study 12107236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12107236 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 7
Study 11772142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day or 10 mg twice daily
Number of subjects: 16
Study 11772142 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole
Number of subjects: 16
Study 11772142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/day
Number of subjects: 16
Study 11772142 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg/day
Number of subjects: 16
Study 11772142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole plus clarithromycin and amoxicillin
Number of subjects: 16
Study 11772142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 to 40 mg/day
Number of subjects: 16
Study 11772142 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 to 40 mg/day
Number of subjects: 16
Study 11772142 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 60 to 120 mg/day
Number of subjects: 16
Study 9698638 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom specific subscales from the Multiscore Depression Inventory
Number of subjects: 20
Study 9698638 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 women without symptomatic premenstrual change)
Number of subjects: 20
Study 7735957 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg anti-TNF alpha-antibody
Number of subjects: 20
Study 7735957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg anti-TNF alpha-antibody
Number of subjects: 20
Study 7735957 — intervention group
Group type: COMPARATOR
Intervention: Comparison with complete murine monoclonal anti-TNF alpha-antibody
Number of subjects: 20
Study 2492140 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe(111)‐EDTA fortified masala (curry powder)
Number of subjects: 0
Study 2492140 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-fortified)
Number of subjects: 0
Study 786416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 32
Study 7376045 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy
Number of subjects: 40
Study 7376045 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and gastroenterostomy
Number of subjects: 40
Study 7376045 — intervention group
Group type: COMPARATOR
Intervention: Both operations
Number of subjects: 40
Study 30596472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary electrocardiogram guidance
Number of subjects: 2250
Study 30596472 — intervention group
Group type: COMPARATOR
Intervention: Anatomical landmark guidance
Number of subjects: 2250
Study 30467335 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIFE1 (lidocaine plus diclofenac)
Number of subjects: 120
Study 30467335 — intervention group
Group type: COMPARATOR
Intervention: CLIFE2 (lidocaine)
Number of subjects: 120
Study 26551066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Viscoseal) 10 mL intra-articularly
Number of subjects: 48
Study 26551066 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 10 mL intra-articularly
Number of subjects: 48
Study 24439974 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninephrectomy (reduction in GFR)
Number of subjects: 440
Study 24439974 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 440
Study 22484026 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical infraclavicular approach (n=30)
Number of subjects: 60
Study 22484026 — intervention group
Group type: COMPARATOR
Intervention: Coracoid infraclavicular approach (n=30)
Number of subjects: 60
Study 21490989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) applied at 1 Hz during canine retraction for 5.0 ± 0.6 months.
Number of subjects: 10
Study 21490989 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEMF exposure).
Number of subjects: 10
Study 17200358 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin 100 mg/m² and Cyclophosphamide 600 mg/m² (EC) every 10 to 11 days for four cycles followed by Paclitaxel 175 mg/m² every 10 to 11 days for four cycles with filgrastim support (300 microg s.c. daily) from day 2 to 24 hours before the next treatment
Number of subjects: 39
Study 16154376 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of peritoneum
Number of subjects: 170
Study 16154376 — intervention group
Group type: COMPARATOR
Intervention: Closure of peritoneum
Number of subjects: 170
Study 12415444 — intervention group
Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 9
Study 12415444 — intervention group
Group type: COMPARATOR
Intervention: HH
Number of subjects: 9
Study 10730909 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (Lamisil)
Number of subjects: 0
Study 10730909 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (Sporanox)
Number of subjects: 0
Study 8867004 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1901527 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 1901527 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 21
Study 1901527 — intervention group
Group type: COMPARATOR
Intervention: Bruce protocol exercise testing
Number of subjects: 21
Study 1901527 — intervention group
Group type: COMPARATOR
Intervention: Less-strenuous, prolonged exercise protocol
Number of subjects: 21
Study 6281293 — intervention group
Group type: EXPERIMENTAL
Intervention: MK 421 (20 mg orally, twice daily)
Number of subjects: 8
Study 6281293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6281293 — intervention group
Group type: EXPERIMENTAL
Intervention: MK 421
Number of subjects: 8
Study 31968571 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Mg supplementation (400 mg/day, Mg Oxide)
Number of subjects: 59
Study 31362715 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month ART refill in Intervention ACs, meeting twice annually.
Number of subjects: 0
Study 31362715 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) ART refill in SoC ACs, meeting five times annually with two-month ART refills.
Number of subjects: 0
Study 30594153 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (perioperative arm): 2 cycles nab‐paclitaxel (125 mg/m2)/gemcitabine (1000 mg/m2, d1, 8 and 15 of a 28 day‐cycle) followed by tumor surgery followed by 4 cycles nab‐paclitaxel/gemcitabine
Number of subjects: 166
Study 30594153 — intervention group
Group type: COMPARATOR
Intervention: Arm B (adjuvant arm): tumor surgery followed by 6 cycles nab‐paclitaxel/gemcitabine
Number of subjects: 166
Study 26824587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR)
Number of subjects: 209
Study 26824587 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 209
Study 24518280 — intervention group
Group type: EXPERIMENTAL
Intervention: LYM-X-SORB™ (LXS) dietary supplements
Number of subjects: 63
Study 24518280 — intervention group
Group type: COMPARATOR
Intervention: Placebo dietary supplements
Number of subjects: 63
Study 22997994 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive antiarrhythmic drugs (AADs) therapy (class Ic and III AADs)
Number of subjects: 123
Study 22997994 — intervention group
Group type: COMPARATOR
Intervention: One AAD therapy (class Ic or III AADs alone)
Number of subjects: 123
Study 20678685 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (new generic losartan potassium 50-mg tablet)
Number of subjects: 27
Study 20678685 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (branded losartan potassium 50-mg tablet)
Number of subjects: 27
Study 20678685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 27
Study 20678685 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation
Number of subjects: 27
Study 20678685 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 27
Study 17363041 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression
Number of subjects: 0
Study 15735276 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous telemetry system linking rural ambulances to a coronary care unit.
Number of subjects: 213
Study 15735276 — intervention group
Group type: COMPARATOR
Intervention: Standard paramedic treatment (Control).
Number of subjects: 213
Study 15735276 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous telemetry system.
Number of subjects: 213
Study 15189574 — intervention group
Group type: EXPERIMENTAL
Intervention: Event frequency manipulation in Study 1
Number of subjects: 0
Study 15189574 — intervention group
Group type: EXPERIMENTAL
Intervention: Egocentrism in Study 2
Number of subjects: 0
Study 15189574 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived frequency of events in Study 3
Number of subjects: 0
Study 15189574 — intervention group
Group type: EXPERIMENTAL
Intervention: Path analyses
Number of subjects: 0
Study 10078770 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 exercises
Number of subjects: 15
Study 10078770 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 exercises
Number of subjects: 15
Study 10078770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 exercises
Number of subjects: 15
Study 10078770 — intervention group
Group type: COMPARATOR
Intervention: Self-report measurement of compliance
Number of subjects: 15
Study 7732999 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform ICDs
Number of subjects: 27
Study 7732999 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic waveform ICDs
Number of subjects: 27
Study 7732999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall implantation
Number of subjects: 27
Study 7732999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall procedure
Number of subjects: 27
Study 7732999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall complications
Number of subjects: 27
Study 7732999 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall follow-up
Number of subjects: 27
Study 2076228 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing sealant
Number of subjects: 20
Study 2076228 — intervention group
Group type: COMPARATOR
Intervention: Conventional fissure sealant
Number of subjects: 20
Study 394267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein (ceruletide) 0.3 mcg/kg intravenously every 4 hours
Number of subjects: 25
Study 394267 — intervention group
Group type: COMPARATOR
Intervention: Control group (no caerulein)
Number of subjects: 25
Study 394267 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein (ceruletide)
Number of subjects: 25
Study 29868778 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 402
Study 29868778 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 402
Study 26994510 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban
Number of subjects: 21105
Study 26994510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban
Number of subjects: 21105
Study 26994510 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 25222386 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy plus CABG (610 patients)
Number of subjects: 1212
Study 25222386 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (602 patients)
Number of subjects: 1212
Study 22333485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg once daily
Number of subjects: 8606
Study 22333485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8606
Study 20209409 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g/100 ml) administered 15 min before the end of surgery and every 6 h for 24 h
Number of subjects: 50
Study 20209409 — intervention group
Group type: COMPARATOR
Intervention: Control group received saline administration (100 ml) 15 min before the end of surgery and every 6 h for 24 h
Number of subjects: 50
Study 20209409 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received tramadol i.v. via a PCA device
Number of subjects: 50
Study 18380845 — intervention group
Group type: COMPARATOR
Intervention: Air drying alone (with an air syringe) during the placement of the dentin adhesive on the ground‐flat occlusal dentin surface (Control Group 1)
Number of subjects: 15
Study 18380845 — intervention group
Group type: EXPERIMENTAL
Intervention: Air drying alone (with an air syringe) during the placement of the dentin adhesive on a standardized MOD cavity (Group 2)
Number of subjects: 15
Study 18380845 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction drying alone in the standardized MOD cavity (Group 3)
Number of subjects: 15
Study 16060402 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural catheterization
Number of subjects: 45
Study 16060402 — intervention group
Group type: COMPARATOR
Intervention: Cephalic epidural catheterization
Number of subjects: 45